• Saved

MEK inhibitors for the treatment of non-small cell lung cancer

MEK inhibitors for the treatment of non-small cell lung cancer

Source : https://link.springer.com/article/10.1186/s13045-020-01025-7

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway.